Laura Blaskowitz-Bantz

Skilled clinical data manager with strong background in managing and analyzing complex datasets for clinical trials. Expertise in ensuring data integrity, regulatory compliance, and process optimization. Known for collaborative approach, adaptability, and consistent delivery of impactful results. Proficient in data management software, database design, and team leadership.

• Training while employed at PPD is available upon request.
• English literature classes with focus on a M.A. in English, Winthrop University, Rock Hill, SC, USA 48 credit hours completed.
• General education classes with focus on a B.A. in English, College of Charleston, Charleston, SC, USA, 45 credit hours completed.

• Endocrinology/Metabolic: Propionic Acidemia, Methylmalonic Acidemia
• Genitourinary: Chronic Kidney Disease
• Hematology: Anemia
• Infectious Disease: Rabies
• Oncology: Non-Small cell lung cancer
• Other Areas of Expertise: Renal Failure
• Respiratory: Asthma, seasonal allergic rhinitis (SAR)

• Endocrinology/Metabolic: A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of Therapeutic Agent in Participants with Propionic Acidemia.
• Endocrinology/Metabolic: A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Therapeutic Agent in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency.
• Infectious Disease: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of Therapeutic Agent in Adults Aged 18 Years and Older.
• Hematology/Genitourinary: A Phase 3 randomized, open-label, active-controlled, parallel-group, multicenter, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of XXX compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
• Hematology/Genitourinary: A Phase 3 randomized, open-label, active-controlled, parallel-group, multicenter, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of XXX compared to XXX.
• Hematology: Genitourinary: A 52-week open-label, randomized, active-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of XXX compared to recombinant human erythropoietin in subjects with anemia associated with chronic kidney disease who are initiating dialysis.
• Genitourinary: A Phase 3, prospective, multicenter, double-blind, randomized, active control study to demonstrate the safety and effectiveness of XXX in preventing catheter-related bloodstream infections in subjects receiving hemodialysis therapy as treatment for end stage renal disease.
• Infections/Parasitic Disease: A Phase 2b randomized blinded study to evaluate XXX compared to human rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in adults with different rabies exposure risks.
• Oncology: A master protocol of phase II studies of XXX in advanced NSCLC: XXX as maintenance after induction chemotherapy or as first line treatment, alone or in combination of standard of care therapies.
• Respiratory: A 52-Week double-blind, placebo-controlled, parallel-group efficacy and safety study of XXX, subcutaneous dosing in patients with uncontrolled asthma and elevated blood eosinophils.
• Respiratory: A randomized, single-blind, parallel-group, placebo-controlled, multidose study comparing the therapeutic equivalence of XXX inhaler and XXX inhaler, each delivering XXX in adult subjects with asthma.
• Respiratory: A double-blind, randomized, parallel-group seasonal allergic rhinitis (SAR) study to evaluate the efficacy, safety and tolerability XXX compared with placebo and individual monotherapy formulations in adult and adolescent subjects.

• MS Office: Word, Excel, PowerPoint, Windows OS
• CTMS
• EDC: Medidata Rave